A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma:the RILOMET-2 trial [abstract]
Convenient once-daily tablet format for easy use
Researchers interested in understanding the broader context of GLP-1 receptor agonist research can explore how tirzepatide compares to other compounds in this class through our semaglutide versus tirzepatide comparison , the mazdutide comparison , and our overview of peptides for weight loss more broadly
In-house physical therapy with therapists experienced in stenosis-specific flexion protocols and aquatic therapy
Dr Caplan really knows her stuff
The combination of GSH with amikacin and DNase I resulted in the most substantial reduction in biofilm viability, promoting fibroblast growth while simultaneously reducing bacterial adhesion